Pfizer awarded $3.5 billion contract by U.S. Army to produce COVID-19 vaccines

  • The Pentagon said on Monday that the U.S. Army has awarded Pfizer (NYSE:PFE) a contract valued at $3.5B to manufacture 500M doses of the vaccine developed by the company in partnership with BioNTech (NASDAQ:BNTX), New York Post reports.
  • The vaccine deliveries will be earmarked for distribution around the world by the end of next year. Pfizer 's messenger-RNA-based vaccine became the first COVID-19 shot to win the FDA's emergency use authorization in December last year.
  • A few days later, the U.S. government increased its order size for the vaccine by 100M doses, bringing the total number of its orders to 200M doses.
  • In June, it was reported that Pfizer (PFE) agreed to supply the federal government with 500M doses of the vaccine with an option for another 200M doses.
  • The company was set to make the deliveries at a not-for-profit basis, unlike the $19.50 per shot paid by the U.S. in the initial contract.

    For this year the company, based in New York City revenue will be around 81.23 billion USD. This is according to the average of the analysts' estimates. This is hugely more than 2021's revenue of 41.91 billion USD.

    Historical revenues and results Pfizer plus estimates 2021

    aandeel

    The analysts expect for 2021 a net profit of 23.42 billion USD. For this year most of the analysts expect a profit per share of 4.12 USD. With this the price/earnings-ratio is 11.24.

    Huge dividend Pfizer

    Analysts expect a dividend of 1.57 USD per share. Thus the dividend yield equals 3.39 percent. The average dividend yield of the pharmaceutical companies is a low 1.36 percent.

    Newest target prices around 43 USD

    The most recent recommendations for the pharmaceutical company are from Goldman Sachs , JP Morgan and Barclays .

    Pfizer 's market capitalization is based on the number of outstanding shares around 256.28 billion USD. 33

    Historical stock prices Pfizer

    historical stocks pfizer

    At 22.02 the stock trades 2.01 percent higher at 46.31 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Pfizer now in top highest dividend yields in America
    Pfizer to broaden RSV portfolio with deal to acquire ReViral for up to $525 million
    Analysts expect revenue increase Pfizer, quite high dividend
    DoD awards Pfizer $1.4B contract modification for 200M COVID vaccine doses for donation
    Pfizer to begin clinical trials for a COVID-19 shot targeting Delta variant
    India in discussions with Pfizer to obtain 50M doses of COVID-19 vaccine
    Sector news
    Analysts anticipate for 2024 on revenue increase Astrazeneca, high dividend yield
    High dividend yield Sanofi-Aventis
    Sanofi-Aventis in top French dividend returns
    Novartis among highest Swiss dividend stocks
    Analysts expect over 2023 revenue increase UCB
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Analysts: this year best year ever for Carl Zeiss Meditec
    National news
    NXP reaps benefits from FRAMOS collaboration
    Tesla net onder de 500.000 cars per year
    Analysts expect over 2024 revenue decrease Caterpillar
    Analysts expect sales decline Biogen
    Analysts anticipate for 2024 on revenue increase Cognizant
    Analysts expect over 2024 growing sales Colgate-Palmolive
    Analysts expect over 2024 revenue expansion Patterson-UTI Energy, relatively high dividend
    Press news
    Test News
    Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial Progress
    Nokia Board of Directors resolved on issuing shares without consideration to the company and a subsequent directed issuance related to the planned completion of the Infinera Corporation acquisition
    Original-Research: NFON AG (von NuWays AG)
    Original-Research: Nabaltec AG (von NuWays AG)
    Original-Research: mVISE AG (von NuWays AG)
    Invitation to the 13th International Investment Forum (IIF) - [ONLINE] on December 4, 2024
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo